The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells

Clinical and Experimental Immunology

Volumn 166, Issue 3, 2011, Pages 385-392

  Iwamoto, S ^a   Kumamoto, T ^a   Azuma, E ^a   Hirayama, M ^a   Ito, M ^a   Amano, K ^a   Ido, M ^b   Komada, Y ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Allostimulatory capacity; Co stimulatory molecules; Cytokines; Dendritic cells; Nuclear factor (NF) B

Indexed keywords

AZITHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; FEMALE; IMMUNOPHENOTYPING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; AZITHROMYCIN; BONE MARROW CELLS; CHOLECALCIFEROL; CLARITHROMYCIN; CYTOKINES; DENDRITIC CELLS; FEMALE; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C57BL; NF-KAPPA B; TOLL-LIKE RECEPTOR 4;

EID: 80855151595     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04480.x     Document Type: Article

References (46)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
2. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445-9.
3. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388:782-7.
4. + T cells. J Immunol 1995; 154:5071-9.
5. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184:747-52.
6. Kobayashi M, Azuma E, Ido M etal. A pivotal role of Rho GTPase in the regulation of morphology and function of dendritic cells. J Immunol 2001; 167:3585-91.
7. Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 1998; 188:2175-80.
8. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001; 13:675-83.
9. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 2000; 96:1039-46.
10. Haidinger M, Poglitsch M, Geyeregger R etal. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185:3919-31.
11. van de Laar L, Buitenhuis M, Wensveen FM, Janssen HL, Coffer PJ, Woltman AM. Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase-protein kinase B-mammalian target of rapamycin signaling. J Immunol 2010; 184:6600-11.
12. Falvo JV, Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995; 80:529-32.
13. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995; 9:2723-35.
14. 3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101:252-62.
15. 3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164:2405-11.
16. Hernández-Presa MA, Bustos C, Ortego M, Tuñón J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998; 153:1825-37.
17. Aljada A, Garg R, Ghanim H etal. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 2001; 86:3250-6.
18. Appel S, Mirakaj V, Bringmann A, Weck MM, Grünebach F, Brossart P. PPAR-gamma agonists inhibit Toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 2005; 106:3888-94.
19. Miller SA, Selzman CH, Shames BD, Barton HA, Johnson SM, Harken AH. Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. J Surg Res 2000; 90:76-81.
20. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T. Clarithromycin HTFS inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001; 45:44-7.
21. Aghai ZH, Kode A, Saslow JG etal. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007; 62:483-8.
22. Sugiyama K, Shirai R, Mukae H etal. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 2007; 147:540-6.
23. Lutz MB, Kukutsch N, Ogilvie AL etal. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223:77-92.
24. Fukao T, Tanabe M, Terauchi Y etal. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 2002; 3:875-81.
25. Shionoiri H, Yasuda G, Abe Y, Yoshimura H, Kaneko Y, Shindo Y. Pharmacokinetics and acute effect on the rennin-angiotensin system of delapril in patients with chronic renal failure. Clin Nephrol 1987; 27:65-70.
26. Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997; 37:1114-20.
27. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998; 42:927-29.
28. Morris DL, De Souza A, Jones JA, Morgan WE. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur J Clin Microbiol Infect Dis 1991; 10:859-61.
29. Errin L, Lagow D, Carson D. Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-γ and tumor necrosis factor-α. J Cell Biochem 2002; 86:759-72.
30. Griffin MD, Lutz WH, Phan VA, Bachman LA, McKean DJ, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000; 270:701-8.
31. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33:277-82.
32. Mahnke K, Guo M, Lee S etal. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000; 151:673-84.
33. Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-32.
34. Shlomchik WD, Couzens MS, Tang CB etal. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412-15.
35. Teshima T, Ordemann R, Reddy P etal. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8:575-81.
36. Taylor PA, Ehrhardt MJ, Lees CJ etal. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007; 110:3480-8.
37. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-61.
38. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003; 18:367-79.
39. Fujita S, Seino K, Sato K etal. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 2006; 107:3656-64.
40. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003; 101:3581-89.
41. Fujita S, Sato Y, Sato K etal. Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells. Blood 2007; 110:3793-803.
42. Fujita S, Yamashita N, Ishii Y etal. Regulatory dendritic cells protect against allergic airway inflammation in a murine asthmatic model. J Allergy Clin Immunol 2008; 121:95-104.
43. Hoshino K, Takeuchi O, Kawai T etal. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-52.
44. An H, Yu Y, Zhang M etal. Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology 2002; 106:38-45.
45. Park JY, Kim HY, Lee JY etal. Macrolide-affected Toll-like receptor 4 expression from Helicobacter pylori-infected monocytes does not modify interleukin-8 production. FEMS Immunol Med Microbiol 2005; 44:171-6.
46. Sato S, Nomura F, Kawai T etal. Synergy and cross-tolerance between Toll-like receptor (TLR)2- and TLR4-mediated signaling pathways. J Immunol 2000; 165:7096-101.